

भारत सरकार
रसायन और उर्वरक मंत्रालय
औषध विभाग
राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण

नई दिल्ली, तारीख: 26 जून, 2019

वक्रक

dk vk % Hkjr ljdkj ds jlk; u vkj mojd ea-ky; }kjk tkjh dk0 vk0 1394½ rkjh[k 30 eb] 2013 vkj dk0 vk0 701½ rkjh[k 10 ekp] 2016 ds l kfk ifBr vksk/k vcher fu; a.k½ vksk] 2013 ds ijk 5, 11 vkj 15 }kjk inRr 'kDr; ka dk iz;ks djrs gq] jk"Vh; vksk/k eW; fu/kkZ.k ikf/kdj.k vftl dks l f{kr : i ea, uihh, dgk tkrk g\$ uhrs dh l kj.kh ds Lrkk ½ ea fofufnZV [kqjk eW; dks mDr l kj.kh ds Lrkk ¼½ ¼½ vkj ½ ea rRLFkuh ifof"V; ka ea fofufnZV izyark] bdkbZ ¼ fuV½ vkj fofuekrk vkj foi.ku dEifu; ka dsuke l fgr Lrkk ½ ea dh rRLFkuh ifof"V ea l s iR; d dh] oLrq, oa l ok dj] ; fn dkbZ g\$ dks NkMlej vf/kdre [kqjk eW; ds : i ea fu; r djrh g\$

l kj.kh

dz la	vud fpr fofufeir dk uke@ckM dk uke	izyark	bdkbZ	fofuekrk vkj foi.ku da uh	[kqjk eW; %½
(1)	(2)	(3)	(4)	(5)	(6)
1.	VØkyel vkmVeW/ %kbyel 0-1% 10 xke½	iR; d xte vkmVeW/ ea 'kfeY g% VØkyel vkbh 1 xte ¼0 xte i d½	1 xte	e l l l ,fyuk g\$Fkd; j ik-fy-@e l l l ek; yu QkekL; fVdYl ik-fy-	30.89
2.	VØkyel vkmVeW/ %kbyel 0-1% 20 xke½	iR; d xte vkmVeW/ ea 'kfeY g% VØkyel vkbh 1 xte ¼20 xte i d½	1 xte	e l l l ,fyuk g\$Fkd; j ik-fy-@e l l l ek; yu QkekL; fVdYl ik-fy-	30.89
3.	, ekDl hfl yhu \$ ikv's'k; e DykoykuV/ l l i s ku	iR; d 5 fefy- fjd kM LVHVM l l i s ku e% , ekDl hfl yhu fVgkbMv/ vkbh ds cjkj , ekDl hfl yhu 400 feXk] ikv's'k; e DykoykuV/ fMyfVM vkbh ds cjkj DykoykuV/ , fl M 57 feXk-	1 fefy-	e l l l cDl yskjVjht fy-@e l l l bM/kl QkekL; fVdYl fy-	3.28
4.	e l k i s y s y \$, eykMi kbu xlyh	iR; d fQYe fyir xlyh e% e l k i s y s y l q huV vkbh 23-75 feXk- ds cjkj e l k i s y s y Vkj VV/ 25 feXk-] ¼ i s y k M f j f y t QkM e \$, eykMi kbu fcl kbyV/ vkbh ds cjkj , eykMi kbu 5 feXk-	1 xlyh	e l l l f o M y k l ck; k/ d fy-@e l l l , CkM g\$Fkd; j ik-fy-	5.58
5.	, VjokLVkFVu \$ Dykfi Mksay dSl y	iR; d gMz tsyVU dSl y e% , VjokLVkFVu dSY'k; e vkbh ds cjkj , VjokLVkFVu 20 feXk ¼ y V/ l e \$ Dykfi Mksay ckl YQV vkbh ds cjkj Dykfi Mksay 75 feXk ¼ y V/ l e \$	1 dSl y	e l l l l k; ukde QkekL; fVdYl fy-@e l l l l h i y k fy-	16.73
6.	, VjokLVkFVu \$ foVfkeu Mh3 xlyh	iR; d fQYe fyir xlyh e% , VjokLVkFVu dSY'k; e vkbh ds cjkj , VjokLVkFVu 10 feXk-] foVfkeu Mh3 % d k y d S Y l Q j k y ½ vkbh 1000 vkbZ w	1 xlyh	e l l l l u QkekL; yskjVjht fy-	9.18
7.	, VjokLVkFVu \$ foVfkeu Mh3 xlyh	iR; d fQYe fyir xlyh e% , VjokLVkFVu dSY'k; e vkbh ds cjkj , VjokLVkFVu 20 feXk-] foVfkeu Mh3 % d k y d S Y l Q j k y ½ vkbh 1000 vkbZ	1 xlyh	e l l l l u QkekL; yskjVjht fy-	16.12
8.	vkyed kVU \$ eMkDl kfeY \$, eykMi kbu \$ Dykfi kkyhMku xlyh	iR; d fQYe fyir xlyh e% vkyed kVU eMkDl kfeY vkbh 20 feXk- , eykMi kbu fcl kbyV/ ds cjkj , eykMi kbu 5 feXk-] Dykfi kkyhMku vkbh 12-5 feXk-	1 xlyh	e l l l l u QkekL; yskjVjht fy-	9.65
9.	vkyed kVU \$ eMkDl kfeY	iR; d fQYe fyir xlyh e%	1 xlyh	e l l l l u QkekL; yskjVjht	15.83

	\$,eyksMikbu \$ DyktjFkyhMksu xlysh	vksyef kVU eMkDI kfey vkbã h 40 fekt- ,eyksMikbu fcl kbyã/ dscjkj ,eyksMikbu 5 fekt-] DyktjFkyhMksu vkbã h 12-5 fekt-		fy-	
10.	jkt:øklVkfVu \$,flifju \$ DyktiMksay dSI y	iR; d gkMZ tsyfVu dSI y e% jkt:øklVkfVu dSY'k; e vkbã h dscjkj jkt:øklVkfVu 10 fekt-%QYe fyfir xlysh eã , flifju vkbã h 75 fekt- ¼ flifju xLVtjfi LVã/ xlysh DyktiMksay ckbI YQV vkbã h dscjkj DyktiMksay 75 fekt- %QYe fyfir xlysh eã	1 dSI y	eSI IZ, dEI MXI ,M QkekL; fVdYI fy-@eSI IZ buVki QkekL; fVdYI fy-	11.15
11.	jkt:øklVkfVu \$,flifju \$ DyktiMksay dSI y	iR; d gkMZ tsyfVu dSI y e% jkt:øklVkfVu dSY'k; e vkbã h dscjkj jkt:øklVkfVu 20 fekt-%QYe fyfir xlysh eã , flifju vkbã h 75 fekt- ¼ flifju xLVtjfi LVã/ xlysh DyktiMksay ckbI YQV vkbã h dscjkj DyktiMksay 75 fekt- %QYe fyfir xlysh eã	1 dSI y	eSI IZ, dEI MXI ,M QkekL; fVdYI fy-@eSI IZ buVki QkekL; fVdYI fy-	16.82
12.	ijfkl Vkeky \$ eQufed , fl M I Liãku	iR; d 5 feky- I Liãku e% ijfkl Vkeky vkbã h 250 fekt-] eQufed , fl M vkbã h 100 fekt-	1 feky-	eSI IZfr: ifr eSI Mdšj fy- @eSI IZ bã/kl QkekL; fVdYI fy-	0.63
13.	DyktiMksay \$,flifju xlysh	iR; d fQYe fyfir xlysh e% DyktiMksay ckbI YQV vkbã h dscjkj DyktiMksay 75 fekt-] , flifju vkbã h ¼ fVd fyfir eã 75 fekt-	1 xlysh	eSI IZ I u QkekL yskj Vjht fy-	3.48
14.	DyktiMksay \$,flifju xlysh	iR; d fQYe fyfir xlysh e% DyktiMksay ckbI YQV vkbã h dscjkj DyktiMksay 75 fekt-] , flifju vkbã h ¼ fVd fyfir eã 150 fekt-	1 xlysh	eSI IZ I u QkekL yskj Vjht fy-	3.55

ukV/ %

¼d½ mi; Ør nh xbz fofufnZV QkMZysku ds fofuekãk vFkãr tks pubZ MxãB Mhi hl hvkš 2013 ds ijlxkQ 2¼ h ds rgr mi; Ør nh xbz I kj.kh ds Lrãk ¼½ ea fofufnZV [kqjk eW; fu/kãjãr djãkã

¼k½ vxj fuekãk vka us mi; Ør I kj.kh ds Lrãk (6) ea of.kãr vf/kdre dher ij I jdkj dks okLro ea Hkãrku fd;k gS; k ; g nš gS rks os oLrq, oal ok dj dks tkãM+ I drsgã

¼x½ vksk/k vew; fu; ã.k½ vknškj 2013 ds ijlxkQ 11 ea fn, x, iko/kkuka ds rgr fuekãk vka dks mi; Ør I kj.kh ds Lrãk ¼½ ea fofufnZV [kqjk eW; ds vk/kkj ij vuq ðpr fofufeãr; ka ds iãka ds fy, [kqjk eW; fu/kãjãr djãkã fuekãk vksk/k vew; fu; ã.k½ vknškj 2013 ds ijlxkQ 24 ds rgr QkMZ V ea vf/kl wuk dh rkjh[k l s, d eW; I ph , uihih, dks vkbã hMh, e, l dsek; e l s tkjh djãr Fkã ml dh dki W jkT; vksk/k fu; ã-dka vksj fofuekãk forj dka dks tkjh djãkã

¼k½ vksk/k vew; fu; ã.k½ vknškj 2013 ds 24 (4) ds micaãka ds vuq kj iR; d QVdj fodãk vksj forjd fofuekãk jkjk fn, x, : i ea , d s i f j l j] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd ml l s ijke'kz ds bPNd fd l h 0; fDr ds fy, igp vkl ku gkš ogkam l dsfd l h l gtn'; Hkx ij dher I ph vksj ij d I phj ; fn dkbz gkš dks lãnf'kãr djãkã

¼M-½ mi; Ør xj vf/kdre dher ¼[kqjk eW; ½ dny mi; Ør fuekãk@foi.ku ds fy, ykxwgS tS k fd mlgkãus vksk/k vew; fu; ã.k½ vknškj 2013 ds rgr vuq) eW; fu/kãjãr.k@lãkku ds fy, QkMZ I ij tek fd;k x;k Fkã vksj I jdkj jkjk fu/kãjãr I Hkã ykxw oSkkfud vko'; drvka dh iãrZ ds v/khu iklãxd fofk;k; k@fu; eka ds vlrãr tS k fd dãnh; @jkT; ykblãlã vknškj Vh ds l {ke ikf/kdkjh jkjk eã; QDpfjã ykblãlã eãgh ds rgr lãr/kr fofufeãr fuekãk@foi.ku dEi fu; ka tks vuqkyu djrh gã

¼p½ fofuekãk ; k foi.ku dEi uh] mijkDr fofufeãr; ka vksj fofufnZV 'krkã dk ikyu ugha djrh gã rks os vko'; d oLrq; vf/kfu; e] 1955 ds l fKã ifBr Mhi hl hvkš 2013 ds iko/kkuka ds v/khu C; kt I fgr vf/ki Hkãjãr jk'k dks tek djus ds fy, nk; h gkãkã

¼N½ bl vknšk ea mijkDr I kj.kh ds Lrãk ¼½ ea dh rRLFkkuh i fof"V ea fofufnZV fofufeãr; ka ds iãka dh [kqjk eW; fu; r gkãus ds ijf.kkeLo#i] vknšk tksfd bl vknšk l s i d l tkjh gq gš Lor%gh fu jLr gks tk; ãkã

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, 26th June, 2019

ORDER

S. O. In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Tacrolimus Ointment (MYLIMUS 0.1% 10gm)	Each gm of Ointment contains: Tacrolimus IP 1mg (10gm pack)	1gm	M/s Alina Healthcare Pvt. Ltd. / M/s Mylan Pharmaceuticals Private Limited	30.89
2.	Tacrolimus Ointment (MYLIMUS 0.1% 20gm)	Each gm of Ointment contains: Tacrolimus IP 1mg (20gm pack)	1gm	M/s Alina Healthcare Pvt. Ltd. / M/s Mylan Pharmaceuticals Private Limited	30.89
3.	Amoxicillin + Potassium Clavulanate Suspension	Each 5ml of reconstituted suspension contains: Amoxicillin Trihydrate IP eq. to Amoxicillin 400mg, Potassium Clavulanate Diluted IP eq. to Clavulanic acid 57mg	1 ML	M/s Brooks Laboratories Ltd. / M/s Intas Pharmaceuticals Limited	3.28
4.	Metoprolol+ + Amlodipine Tablet	Each film coated tablet contains: Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg, (as prolonged release form), Amlodipine Besylate IP eq. to Amlodipine 5mg.	1 Tablet	M/s Windlas Biotech Limited / M/s Abbott Healthcare Pvt. Ltd.	5.58
5.	Atorvastatin + Clopidogrel Capsule	Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Limited	16.73
6.	Atorvastatin + Vitamin D3 Tablet	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 10mg	1 Tablet	M/s Sun Pharma Laboratories Limited	9.18

		Vitamin D3 (Cholecalciferol) IP 1000 IU			
7.	Atorvastatin + Vitamin D3 Tablet	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg Vitamin D3 (Cholecalciferol) IP 1000 IU	1 Tablet	M/s Sun Pharma Laboratories Limited	16.12
8.	Olmesartan Medoxomil + Amlodipine + Chlorthalidone Tablet	Each film coated tablet contains: Olmesartan Medoxomil IP 20mg Amlodipine Besylate IP eq. to Amlodipine 5mg Chlorthalidone IP 12.5mg	1 Tablet	M/s Sun Pharma Laboratories Limited	9.65
9.	Olmesartan Medoxomil + Amlodipine + Chlorthalidone Tablet	Each film coated tablet contains: Olmesartan Medoxomil IP 40mg, Amlodipine Besylate IP eq. to Amlodipine 5mg Chlorthalidone IP 12.5mg	1 Tablet	M/s Sun Pharma Laboratories Limited	15.83
10.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (As Film coated Tablet), Aspirin IP 75mg (As Aspirin Gastro – resistant Tablets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet)	1 Capsule	M/s Akums Drugs & Pharmaceuticals Limited / M/s Intas Pharmaceuticals Limited	11.15
11.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Film coated Tablet), Aspirin IP 75mg (As Aspirin Gastro – resistant Tablets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet)	1 Capsule	M/s Akums Drugs & Pharmaceuticals Limited / M/s Intas Pharmaceuticals Limited	16.82
12.	Paracetamol + Mefenamic Acid Suspension	Each 5ml Suspension contains: Paracetamol IP 250mg Mefenamic Acid IP 100mg	1 ML	M/s Tirupati Medicare Limited / M/s Intas Pharmaceuticals Limited	0.63
13.	Clopidogrel + Aspirin Tablet	Each film coated tablet contains: Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg Aspirin IP (As enteric coated) 75mg	1 Tablet	M/s Sun Pharma Laboratories Limited	3.48
14.	Clopidogrel + Aspirin Tablet	Each film coated tablet contains: Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg Aspirin IP (As enteric coated) 150mg	1 Tablet	M/s Sun Pharma Laboratories Limited	3.55

Note:

- (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/200/68/2019/F

F. No. 8(68)/2019/D.P./NPPA-Div.-II

(Prasenjit Das)
Assistant Director